Is Cerebrolysin approved outside the US?

What Cerebrolysin is

Cerebrolysin is a neuropeptide preparation: a purified mixture of small peptides and amino acids derived from pig brain protein, developed and manufactured in Austria. It has been in clinical use across Europe and Asia for decades, and it is one of the most studied brain-directed peptide products in the world, with a body of randomised human trials behind it that most cognitive peptides do not have.

It is used as a prescription medicine, given by injection or infusion under medical supervision, most often in neurology settings: recovery after stroke, traumatic brain injury, and dementia.

The rationale is neurotrophic. The peptide fragments in Cerebrolysin are thought to act in a way similar to the brain's own growth-and-repair signals (neurotrophic factors such as BDNF), supporting the survival of neurons, the formation of new connections between them (neuroplasticity), and repair after injury. That is why its authorised uses cluster around conditions where brain tissue has been damaged or is degenerating.

Unlike most compounds in the nootropic space, Cerebrolysin is not a single synthetic molecule. That detail turns out to matter a great deal for the question this page answers: why a product authorised in more than 50 countries has never been approved in the United States.

The short answer

• Yes, in more than 50 countries. Cerebrolysin holds marketing authorisation across Europe, Asia and elsewhere, including Austria (its country of origin), Russia, China and South Korea.
• No, not in the United States. It is not FDA-approved for any indication, has never been reviewed under a US New Drug Application, and is not legally marketed for human use there. It is investigational in the US context.
• Indications differ by jurisdiction: acute ischaemic stroke, traumatic brain injury, vascular dementia, Alzheimer's disease. There is no single global indication.
• Two structural reasons for the US gap, neither of them "the evidence was reviewed and rejected": it is a porcine brain-derived multi-component extract, which makes the characterisation the FDA requires genuinely hard; and it is old and off-patent, so no sponsor has a commercial reason to fund a US registrational programme.
• There is real human trial evidence, which most cognitive peptides lack. A Cochrane review in vascular dementia concluded it may improve cognition and global function, while noting that risk of bias and heterogeneity kept the finding from being definitive. In acute ischaemic stroke, a 2023 Cochrane update found no benefit on all-cause death and a significant increase in non-fatal serious adverse events. The picture depends on the condition, which is exactly why this is a physician's call.
• Approval in many countries is not a meta-analysis. A count of jurisdictions tells you about regulatory standards, eras and filings, not about effect size.

Draft: pending MAB review. Educational content, not medical advice. No doses or protocols appear.

---

The question arrives in a particular shape: if this is approved in fifty countries, why isn't it approved in America? The shape carries an implication: that one of the two answers must be a mistake, and that identifying which one settles the matter.

It does not work that way. Approval is a legal status conferred by a specific agency, under a specific statute, on a specific submitted dossier, at a specific point in history. It is a fact about a filing. Cerebrolysin is a clear worked example of how far apart a compound's legal status and its evidential status can sit, and the gap runs in both directions.

This page is about the regulatory geography. What the compound is proposed to do biologically, and how it sits alongside other cognitive peptides, is covered in Dihexa and Cerebrolysin: the cognitive peptides.

Approval is jurisdictional

There is no such thing as a globally approved medicine. There are national and regional marketing authorisations, each granted by an agency applying its own statute to a dossier a sponsor chose to submit to it.

Three consequences follow, and all three are load-bearing here.

A sponsor must file. No agency evaluates a compound on its own initiative. If nobody submits a dossier, the agency has nothing to approve, and the compound remains unapproved in that jurisdiction indefinitely, regardless of how strong or weak the underlying evidence is. Absence of approval in a given country is, first of all, evidence about filings.

Standards and eras differ. An authorisation granted in one country in the 1990s under the evidentiary expectations of that time is a different object from one granted in 2026 under current requirements. The label may look similar. The package behind it is not.

The indication is part of the authorisation. A compound is never simply "approved." It is approved for a stated indication, in a stated population, on a stated dossier. Two countries can authorise the same product for materially different conditions.

The general mechanics of this (filed, approved, available, and why those three are separate states) are set out in filed, approved, available. The same dynamic across a region is worked through in medicine registration in Southeast Asia.

Where Cerebrolysin holds a marketing authorisation

Cerebrolysin originates in Austria, where it is manufactured and authorised, and it holds marketing authorisation in more than 50 countries. The list includes Russia, China and South Korea, alongside numerous countries in Central and Eastern Europe, Central Asia, the Middle East and Latin America.

The indications vary by jurisdiction, and it is worth resisting the temptation to collapse them into one. Across the various authorisations, the conditions named include:

• Acute ischaemic stroke
• Traumatic brain injury
• Vascular dementia
• Alzheimer's disease

No single country's authorisation necessarily covers all four, and the wording, population and conditions of use differ. "Approved for dementia in some countries" is accurate; "approved for dementia" without qualification is not.

The US row is the one people misread. It does not say rejected. It says never filed, which is a materially different fact, and the rest of this page is about why.

Why a US approval has not followed

Two reasons, and they compound. Neither is "the FDA looked at the evidence and said no," because the FDA has not looked: there has been no US New Drug Application to look at.

The characterisation problem

Cerebrolysin is a porcine brain-derived peptide preparation: a biological extract produced by enzymatic breakdown of pig brain tissue, yielding a mixture of low-molecular-weight peptides and free amino acids. It is not a single defined molecule.

This matters more than it might appear. The FDA's drug approval pathway is built around defined, reproducible characterisation: what the substance is, in what proportions, batch to batch, with specifications that a manufacturer can hold to and an inspector can verify. For a synthetic single-entity drug, that is demanding but tractable. For a multi-component extract of animal tissue, it is a substantially harder problem: the active constituents must be identified, the batch-to-batch consistency demonstrated, and the analytical methods validated to a standard that supports a claim.

There are further layers specific to animal-derived starting material: source-animal controls, viral and transmissible-agent safety, and the regulatory classification questions that come with a tissue-derived biological. None of these is insurmountable in principle. All of them add cost, time and technical risk to a filing.

So the characterisation problem is a substantive reason a US submission is hard, not a formality and not a conspiracy.

The sponsor and economics problem

The second reason is simpler and probably decisive on its own.

Cerebrolysin is old and off-patent. A US registrational programme (trials designed to FDA expectations, powered for the relevant endpoints, plus the chemistry, manufacturing and controls work described above) is a major capital commitment. Companies make that commitment because they expect a protected commercial window on the other side of it.

Without exclusivity, a sponsor who funded that programme would establish a result that any competitor could then use. The spreadsheet says no, and so the filing does not happen.

This is the same structural pattern that governs most of the off-patent shelf, and it is worth internalising because it recurs constantly in this field: absent a sponsor, a compound stays unapproved in the US regardless of the evidence. The evidence is not the binding constraint. The filing is.

Note what this does and does not license you to conclude. It explains why the absence of a US approval is weak evidence about efficacy. It does not convert the compound into a proven one; for that you have to look at the trials, which is the next section, and the results vary by condition.

What the trial evidence supports, and where it is contested

Cerebrolysin is better studied in humans than most compounds discussed under the nootropic heading. That is a genuine distinction: there are randomised controlled trials and there are systematic reviews of them. It is not the same as a favourable result, and the honest summary runs in two directions at once.

Acute ischaemic stroke: a negative finding, and a safety signal

The 2023 Cochrane update on Cerebrolysin in acute ischaemic stroke found no beneficial effect on all-cause death. Alongside that, it identified a statistically significant increase in non-fatal serious adverse events.

The efficacy finding is null on the outcome that matters most in acute stroke. The safety finding is not a theoretical concern raised in a discussion section; it is a measured difference in the pooled trial data.

Vascular dementia: a qualified positive, explicitly non-definitive

A Cochrane review in vascular dementia reached a different conclusion: intravenous Cerebrolysin may improve cognition and global function.

The reviewers qualified this carefully, and the qualification is part of the finding rather than a disclaimer attached to it. The conclusion was not definitive, because of high risk of bias in the included studies and substantial heterogeneity between them. Many of the trials were conducted in a limited set of countries, under older methodological conventions, with variation in design, population and outcome measures that makes pooling difficult to interpret.

How to hold the two together

The temptation is to pick the finding you prefer. The two findings concern different conditions, rest on different trial bases, and neither cancels the other, which is what a mixed literature looks like when it is reported honestly.

Across the literature more broadly, effect sizes are modest rather than dramatic, and meta-analyses disagree on magnitude, which is itself informative. When the same trial base yields different pooled estimates depending on inclusion criteria and analytic choices, the underlying signal is not robust.

Stated at tier: this is human randomised evidence, systematically reviewed, with results that are mixed and contested. That is a higher evidence tier than most compounds in this category reach, and a more nuanced result than either its promoters or its critics usually admit. Both statements are true simultaneously. How to read this kind of literature without over- or under-reading it is covered in peptides for concussion and TBI, where the same compound appears in a different clinical frame.

What jurisdictional approval does and does not tell you

Here is the practical conclusion, and it generalises well beyond this one compound.

What "approved in 50+ countries" does tell you. That a sponsor filed in those countries, that each agency found the submitted package adequate under its own standard at the time, and that a regulated manufacturing and pharmacovigilance framework applies locally. Those are real facts and not nothing.

What it does not tell you. It is not a meta-analysis. Counting jurisdictions is not an evidence-synthesis method. Fifty authorisations resting substantially on the same underlying trial base do not constitute fifty independent confirmations: they constitute one body of evidence, assessed fifty times, by agencies applying different standards in different decades.

What "not approved in the US" does tell you. That no sponsor has submitted a New Drug Application. Given the characterisation and economic obstacles above, that absence is largely explained before you reach the question of efficacy at all.

What it does not tell you. It does not mean the FDA evaluated the compound and rejected it. No such evaluation has occurred.

So both intuitions that people bring to this question are wrong in the same way. Approved in fifty countries, so it must work and not approved in America, so it must not are both attempts to read evidence off a legal status. The legal status is a fact about filings and agencies. The evidence is a separate question, and for this compound the evidence is available, reviewed, and mixed, which is the harder and more useful answer.

The general version of this reasoning, applied to a differently-situated compound, is in is Semax legal in 2026.

If your interest is cognitive support

Most people who search for Cerebrolysin are not recovering from a stroke. They want sharper focus, better memory, or more mental stamina, and they have landed on Cerebrolysin because it is the best-known name in the category.

Vivre Labs does not dispense Cerebrolysin. For focus and cognitive goals, the option in the Vivre catalogue is the V-02 Focus protocol, built around Semax and Selank: short synthetic peptides, lot-tested, and best considered only after baseline bloodwork. How those two compare with other cognitive peptides is set out in Semax and Selank.

Frequently asked questions

Is Cerebrolysin FDA approved? No. Cerebrolysin is not approved by the FDA for any indication and is not legally marketed for human use in the United States. It has never been reviewed under a US New Drug Application, meaning there has been no FDA evaluation and no rejection, simply no submission. In the US context it is an investigational compound. This is a statement about its legal status only, and is separate from what the trial evidence shows.

Why is Cerebrolysin not FDA approved if it's approved elsewhere? Two reasons that reinforce each other. First, characterisation: it is a porcine brain-derived peptide preparation, a multi-component biological extract rather than a single defined molecule, and the FDA pathway requires defined, reproducible characterisation that is substantially harder to establish for a tissue-derived mixture. Second, economics: the compound is old and off-patent, so no sponsor has a commercial incentive to fund a US registrational programme. Without a sponsor willing to file, the compound stays unapproved regardless of the evidence either way.

Does approval in more than 50 countries mean it works? No, and this is the central point. A count of jurisdictions is not a method of evidence synthesis. Those authorisations were granted by different agencies, under different standards, in different decades, largely on the same underlying trial base, so they are one body of evidence assessed many times, not many independent confirmations. The evidence has to be read directly, and when it is, it is mixed: a 2023 Cochrane update in acute ischaemic stroke found no benefit on all-cause death alongside a significant increase in non-fatal serious adverse events, while a Cochrane review in vascular dementia found possible improvement in cognition and global function that the reviewers explicitly called non-definitive given high risk of bias and heterogeneity. Effect sizes are modest and meta-analyses disagree on magnitude.

Related reading

• Dihexa and Cerebrolysin: the cognitive peptides: what these compounds are proposed to do
• Peptides for concussion and TBI: the same compound in a clinical frame
• Filed, approved, available: why those three are different states
• Medicine registration in Southeast Asia: jurisdictional approval in practice
• Is Semax legal in 2026?: the same reasoning, a different compound

Part of The Complete Guide to Nootropic Peptides

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Semax.

---

Educational content, not medical advice. This page describes the regulatory status and published evidence base of Cerebrolysin and does not recommend or discourage its use for any individual. Cerebrolysin is not approved by the FDA for any indication and is investigational in the United States; where it is authorised, it is a prescription medicine used under medical supervision and indications differ by jurisdiction. Nothing here describes how any compound is obtained. Regulatory status and evidence both change; verify against current national registers and current systematic reviews. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 24 September 2026. Last reviewed: September 2026.

References

• US regulatory status: Cerebrolysin is not approved by the FDA for any indication, is not legally marketed for human use in the United States, and has never been reviewed under a US New Drug Application. Verify against the FDA's Drugs@FDA database. (accessdata.fda.gov)
• Marketing authorisation outside the US: manufactured in Austria and authorised in more than 50 countries, including Russia, China and South Korea. Authorised indications vary by jurisdiction and span acute ischaemic stroke, traumatic brain injury, vascular dementia and Alzheimer's disease. National registers are the authoritative source for the current label in any given country.
• Product characterisation: Cerebrolysin is a porcine brain-derived peptide preparation: a multi-component biological extract of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of brain tissue, not a single defined molecule. This is the basis of the characterisation obstacle described above.
• Cochrane, acute ischaemic stroke (2023 update): found no beneficial effect on all-cause death, with a statistically significant increase in non-fatal serious adverse events. (cochranelibrary.com)
• Cochrane, vascular dementia: concluded that intravenous Cerebrolysin may improve cognition and global function, while cautioning that the conclusion was not definitive owing to high risk of bias and heterogeneity among included studies. (cochranelibrary.com)
• Heterogeneity of pooled estimates: across the wider literature, reported effect sizes are modest rather than dramatic, and meta-analyses disagree on magnitude depending on inclusion criteria and analytic choices. Disagreement between pooled estimates on a shared trial base is itself evidence that the signal is not robust.
• Trial economics and exclusivity: the dependence of commercial registrational programmes on an expectation of patent exclusivity is well described in the health-economics literature. The structural point, that sponsors fund filings they expect to recoup, is not disputed, and applies to off-patent compounds generally rather than to this one specifically.